Pilot randomized placebo-controlled clinical trial of high-dose gabapentin for alcohol use disorder.

ABSTRACT:

Background

Despite advances in the development of pharmacotherapy for alcohol use disorder (AUD), there remains a need for medications that can be administered to actively drinking outpatients to promote a reduction in harmful alcohol consumption. The primary aim of this pilot study was to determine whether high-dose gabapentin (3600 mg/daily) is more effective than placebo in reducing harmful alcohol consumption in outpatients with AUD.

Methods

Forty patients (27 men) who met DSM-IV-TR criteria for alcohol dependence and reporting at least 4 heavy drinking days (HDD) per week were recruited at a single site. Participants were actively drinking at study entry and received double-blind gabapentin (3600 mg/day; n = 19) or placebo (n = 20) for 8 weeks. Study medication was titr

SUBMITTER: Mariani JJ 

PROVIDER: S-EPMC8462978 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature